Background: Cisplatin is a widely used antineoplastic drug in different types of cancers (ovarian, testicular, and hematological) with several types of adverse effects, including testicular toxicity. Fimasartan is a newer angiotensin-receptor blocker (ARB) that has antioxidant and anti-inflammatory properties. Omega-3 is an unsaturated fatty acid that has antioxidant and anti-inflammatory effects. Objective: to evaluate the protective effects of fimasartan alone or in combination with omega-3 against cisplatin-induced testicular toxicity. Methods: Thirty Wistar rats were divided into five groups: control group, cisplatin-treated group, fimasartan+cisplatin group, fimasartan+omega-3+cisplatin group, and omega-3+cisplatin group. Treatments were administered for 10 consecutive days. On day 10, a single intraperitoneal dose of cisplatin (7mg/kg) was given to induce testicular toxicity. On day 11, animals were sacrificed. Testicular tissue homogenates were used to measure malondialdehyde (MDA), reduced glutathione (GSH), and superoxide dismutase (SOD). Serum levels of testosterone and inhibin-B were measured using ELISA. Histopathological examination of the testes was also performed. Results: Cisplatin administration significantly increased MDA levels and significantly decreased GSH, SOD, testosterone, and inhibin-B levels compared with the control group. Treatment with fimasartan alone or in combination with omega-3 significantly attenuated these alterations and improved histopathological changes in testicular tissue. Conclusions: Fimasartan exerts protective effects against cisplatin-induced testicular toxicity through its antioxidant and reducing oxidative stress effects, and its combination with omega-3 enhances these protective effects.
